Key statistics
On Monday, Astria Therapeutics Inc (ATXS:NMQ) closed at 11.67, -30.95% below its 52-week high of 16.90, set on Mar 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 11.85 |
---|---|
High | 11.85 |
Low | 11.50 |
Bid | 11.50 |
Offer | 12.72 |
Previous close | 11.87 |
Average volume | 544.75k |
---|---|
Shares outstanding | 56.43m |
Free float | 49.67m |
P/E (TTM) | -- |
Market cap | 669.77m USD |
EPS (TTM) | -2.30 USD |
Data delayed at least 15 minutes, as of Oct 07 2024 21:00 BST.
More ▼
Press releases
- Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema
- Astria Therapeutics to Present at Upcoming Global Angioedema Forum
- Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress
- Astria Therapeutics to Present at Upcoming Bradykinin Symposium
- Astria Therapeutics to Participate in Upcoming Morgan Stanley 22nd Annual Global Healthcare Conference
- Astria Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
- Astria Therapeutics Chooses Ypsomed’s YpsoMate as the Injection Device for STAR-0215 for the Treatment of Hereditary Angioedema
- Astria Therapeutics to Participate in Upcoming 2024 Wedbush PacGrow Healthcare Conference
More ▼